Evidence map›Paper›PMID 14747534›Full record

ArticleJournal of virology2004

Human immunodeficiency virus type 1 Nef associates with lipid rafts to downmodulate cell surface CD4 and class I major histocompatibility complex expression and to increase viral infectivity.

Melissa Alexander, Yeou-cherng Bor, Kodimangalam S Ravichandran, Marie-Louise Hammarskjöld, David Rekosh

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 58 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Glycosphingolipid functions.Cold Spring Harbor perspectives in biology · 2011
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Melissa AlexanderMyles H. Thaler Center for AIDS and Human Retrovirus Research, Carter Immunology Center, and the Department of Microbiology, University of Virginia, Charlottesville, Virginia 22908, USA.
Yeou-cherng Bor
Kodimangalam S Ravichandran
Marie-Louise Hammarskjöld
David Rekosh
University of Virginia · USCarter Center · US

Funding

HIV PARTICLE FORMATION AND RNA PACKAGINGR01AI047008 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI REKOSH, DAVID M · 2000 to 2003
$1.0M
REGULATION OF HIV RNA PROCESSING AND TRANSPORTR01AI034721 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI HAMMARSKJOLD, MARIE-LOUISE · 1994 to 2002
$734k
NIAID NIH HHS AI34721NIAID NIH HHS AI47008NIAID NIH HHS R01 AI047008
6 · The paper itself

Abstract

Lipid rafts are membrane microdomains that are functionally distinct from other membrane regions. We have shown that 10% of human immunodeficiency virus type 1 (HIV-1) Nef expressed in SupT1 cells is present in lipid rafts and that this represents virtually all of the membrane-associated Nef. To determine whether raft targeting, rather than simply membrane localization, has functional significance, we created a Nef fusion protein (LAT-Nef) containing the N-terminal 35 amino acids from LAT, a protein that is exclusively localized to rafts. Greater than 90% of the LAT-Nef protein was found in the raft fraction. In contrast, a mutated form, lacking two cysteine palmitoylation sites, showed less than 5% raft localization. Both proteins were equally expressed and targeted nearly exclusively to membranes. The LAT-Nef protein was more efficient than its nonraft mutant counterpart at downmodulating both cell surface CD4 and class I major histocompatibility complex (MHC) expression, as well as in enhancing first-round infectivity and being incorporated into virus particles. This demonstrates that targeting of Nef to lipid rafts is mechanistically important for all of these functions. Compared to wild-type Nef, LAT-Nef downmodulated class I MHC nearly as effectively as the wild-type Nef protein, but was only about 60% as effective for CD4 downmodulation and 30% as effective for infectivity enhancement. Since the LAT-Nef protein was found entirely in rafts while the wild-type Nef protein was distributed 10% in rafts and 90% in the soluble fraction, our results suggest that class I MHC downmodulation by Nef may be performed exclusively by raft-bound Nef. In contrast, CD4 downmodulation and infectivity enhancement may require a non-membrane-bound Nef component as well as the membrane-bound form.

Indexed as

Down-RegulationAnimalsCD4 AntigensCell MembraneChlorocebus aethiopsCOS CellsGene Products, nefHeLa CellsHistocompatibility Antigens Class IHIV-1HumansMembrane Microdomainsnef Gene Products, Human Immunodeficiency VirusCD4 AntigensGene Products, nefHistocompatibility Antigens Class Inef Gene Products, Human Immunodeficiency Virus

Identifiers

PMID14747534
PMCPMC369412
OpenAlexW2131413819

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.